$LGVN #BIOTECH

Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results

First patient dosed in Phase 2 clinical trial of Lomecel-B — Conference call scheduled for 8:30 a.m. ET today — for Aging-Related Frailty in Japan — — New long-term survival data disclosed from ELPIS I trial of Lomecel-B First Quarter Business Updates: Lomecel-B TM for Hypoplastic Left Heart Syndrome (HLHS): for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit — Corporate Updates MIAMI, May 12, 2023 (GLOBE NEWSWIRE) — Longeveron Inc.

$LGVN #BIOTECH

Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023

MIAMI, May 08, 2023 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its first quarter 2023 financial results on Friday, May 12, 2023 before the open of the U.S.

$LGVN

Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

– Data reinforce potential survival benefit of Lomecel-B – Enrollment ongoing in Phase 2a ELPIS II trial – – Lomecel-B has Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation for HLHS Indication – for patients with hypoplastic left heart syndrome (HLHS) – Children in the ELPIS I trial had 100% survival up to 5 years of age after receiving Lomecel-B compared to 20% mortality rate observed from historical control data – MIAMI, May 09, 2023 (GLOBE NEWSWIRE) — Longeveron Inc.